Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 701–800 of 1,005
Taxane-based Combination Therapies for Metastatic Prostate Cancer
Corn, P. G., Agarwal, N., Araujo, J. C., & Sonpavde, G. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.11.009 · Cited by 43
Body, J., von Moos, R., Rider, A., Hallworth, P., Bhowmik, D., Gatta, F., Hechmati, G., & Qian, Y. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.100212 · Cited by 37
Suominen, M. I., Wilson, T., Käkönen, S.-M., & Scholz, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163899 · Cited by 42
“Notably, most of these adverse events were also observed in placebo-treated patients in a randomized phase 3 trial [92].”
BackgroundImmunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer
Adamaki, M., & Zoumpourlis, V. (2021) · Cancers · doi:10.3390/cancers13020173 · Cited by 41
“These include the chemotherapeutic drug cabazitaxel [26], the androgen signaling inhibitors abiraterone, enzalutamide, apalutamide, and darolutamide [27–29], the alpha-emitter bone-seeking radioisotope radium-233 [30,31], and the immunotherapeutic drug Sipuleucel-T [32], all of which have demonstrated significant impr…”
BackgroundFeng, F. Y.-C., Thomas, S., Fred Saad, C., Gormley, M., Yu, M. K., Ricci, D. S., Rooney, B., Brookman-May, S. D., McCarthy, S. A., Olmos, D., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1463 · Cited by 36
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
Gartrell, B. A., & Saad, F. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215592288 · Cited by 40
The aqueous chemistry of radium
Brown, P. L., Matyskin, A. V., & Ekberg, C. H. (2022) · Radiochimica Acta · doi:10.1515/ract-2021-1141 · Cited by 39
Jadvar, H., CHALLA, S., Quinn, D. I., & Conti, P. S. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1802 · Cited by 37
Uemura, K., Miyoshi, Y., Kawahara, T., Yoneyama, S., Hattori, Y., Teranishi, J., Kondo, K., Moriyama, M., Takebayashi, S., Yokomizo, Y., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2160-1 · Cited by 37
Máthé, D., Szigeti, K., Hegedűs, N., Horváth, I., Veres, D. S., Kovács, B., & Szűcs, Z. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.04.015 · Cited by 35
Sequencing Treatment for Castration-Resistant Prostate Cancer
Handy, C. E., & Antonarakis, E. S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0438-9 · Cited by 37
Hegemann, M., Bedke, J., Stenzl, A., & Todenhöfer, T. (2017) · Therapeutic Advances in Urology · doi:10.1177/1756287216686018 · Cited by 43
“The approval of the radionuclide radium-223 has led to a significant improvement of therapeutic options for patients with symptomatic BMs in CRPC [Parker et al. 2013; Fizazi et al. 2011].”
BackgroundPersonalization of prostate cancer therapy through phosphoproteomics
Yang, W., Freeman, M. R., & Kyprianou, N. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0014-0 · Cited by 38
Dellis, A., Zagouri, F., Liontos, M., Mitropoulos, D. N., Bamias, A., & Papatsoris, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.005 · Cited by 41
Darolutamide For Castration-Resistant Prostate Cancer
Bastos, D. A., & Antonarakis, E. S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s197244 · Cited by 35
Seifert, R., Alberts, I., Afshar‐Oromieh, A., & Rahbar, K. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.004 · Cited by 42
Commercial and business aspects of alpha radioligand therapeutics
Ostuni, E., & Taylor, M. R. G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1070497 · Cited by 38
Bambury, R. M., & Rathkopf, D. E. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.05.025 · Cited by 38
Theranostics and Patient-Specific Dosimetry
Bednarz, B. P. (2023) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.03.011 · Cited by 46
Ferretti, S., Mercinelli, C., Marandino, L., Litterio, G., Marchioni, M., & Schips, L. (2023) · Research and Reports in Urology · doi:10.2147/rru.s385257 · Cited by 55
“The overall incidence of adverse events was consistently lower in the radium-223 group than in the placebo group for adverse events of all grades, grade 3 or 4 adverse events, and serious adverse events.(15) The Phase 3 ERA 223 trial randomized patients with chemotherapy-naïve CRPC and asymptomatic or mildly symptomat…”
BackgroundInfluentialIannantuono, G. M., Chandran, E. B. A., Floudas, C. S., Choo‐Wosoba, H., Butera, G., Roselli, M., Gulley, J. L., & Karzai, F. H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102623 · Cited by 40
PARP inhibitors for prostate cancer
Longoria, O., Beije, N., & de Bono, J. S. (2024) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.09.003 · Cited by 34
The Current Therapeutic Landscape for Metastatic Prostate Cancer
Bernal, A. G., Bechler, A., Mohan, K., Rizzino, A., & Mathew, G. (2024) · Pharmaceuticals · doi:10.3390/ph17030351 · Cited by 46
“Thus, resistance to standard therapies contributes to the molecular landscape of NEPC and presents the need to adjust treatment regimens unique to treating or preventing aggressive MNEPC.”
Molife, L. R., Omlin, A. G., Jones, R. J., Karavasilis, V., Bloomfield, D. J., Lumsden, G., Fong, P. C. C., Olmos, D., O’Sullivan, J. M., Pedley, I. D., et al. (2014) · Future Oncology · doi:10.2217/fon.13.250 · Cited by 37
Self-citationAbiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison
Chopra, A., Georgieva, M., Lopes, G. D. L., Jr., Yeo, C. M., & Haaland, B. A. (2017) · The Prostate · doi:10.1002/pros.23309 · Cited by 39
Rahbar, K., Konnert, J., Bögemann, M., Stegger, L., & Bräuer, A. (2017) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0846-16-09 · Cited by 34
“, the results from the ALSYMPCA trial (15), did not include 68Ga-PSMAPET results, the relevance of this PET information is unclear.”
ResultBoegemann, M., Schlack, K., Thomes, S., Steinestel, J., Rahbar, K., Semjonow, A., Schrader, A. J., Aringer, M., & Krabbe, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020380 · Cited by 36
Therapy assessment of bone metastatic disease in the era of 223radium
Etchebehere, E., Brito, A. E., Rezaee, A., Langsteger, W., & Beheshti, M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3734-0 · Cited by 34
“(223)Ra is the first bone-seeking radionuclide that has demonstrated increased OS in mCRPC patients [11].”
BackgroundComplications of bone metastases from malignant melanoma
Zekri, J., Marples, M., Taylor, D., Kandukurti, K., McParland, L., & Brown, J. E. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.08.003 · Cited by 37
Targeted alpha-particle therapy: imaging, dosimetry, and radiation protection
Laßmann, M., & Eberlein, U. (2018) · Annals of the ICRP · doi:10.1177/0146645318756253 · Cited by 36
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer
Nunno, V. D., Gatto, L., Santoni, M., Cimadamore, A., Antonio Lopez-beltran, B., Liang Cheng, C., Scarpelli, M., Montironi, R., & Massari, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00397 · Cited by 34
Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone
Dondossola, E., Casarin, S., Paindelli, C., De‐Juan‐Pardo, E. M., Hutmacher, D. W., Logothetis, C. J., & Friedl, P. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz007 · Cited by 36
Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?
Fay, A. P., & Antonarakis, E. S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.01.37 · Cited by 33
Shore, N. D., Higano, C. S., George, D. J., Sternberg, C. N., Fred Saad, C., TOMBAL, B. F., Miller, K., Kalinovský, J., Jiao, X., Tangirala, K., et al. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-0236-0 · Cited by 34
Self-citationThe potential of PSMA-targeted alpha therapy in the management of prostate cancer
Filippi, L., Chiaravalloti, A., Schillaci, O., & Bagni, O. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1814151 · Cited by 37
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer
Cattrini, C., Navarro, R. E., Mennitto, A., Bersanelli, M., Castro, E., Olmos, D., Lorente, D., & Gennari, A. (2021) · Cancers · doi:10.3390/cancers13184522 · Cited by 37
“Patients had either received docetaxel or were deemed ineligible or refused docetaxel; no patients had received abiraterone or enzalutamide [24].”
BackgroundA Primer on Radiopharmaceutical Therapy
Salerno, K. E., Roy, S., Ribaudo, C., Fisher, T., Patel, R. B., Mena, E., & Escorcia, F. E. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.08.010 · Cited by 40
Todenhöfer, T., Stenzl, A., Hofbauer, L. C., & Rachner, T. D. (2015) · International Journal of Endocrinology · doi:10.1155/2015/838202 · Cited by 36
Bauman, G. S., Corkum, M. T., Fakir, H., Nguyen, T. K., & Palma, D. A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08020-2 · Cited by 33
Fizazi, K. S., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., Blanchard, P., Bossaert, F., Castro, E., Comperat, E., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.015 · Cited by 40
Self-citationNovel agents for castration‐resistant prostate cancer: Early experience and beyond
Fujimoto, N. (2015) · International Journal of Urology · doi:10.1111/iju.12907 · Cited by 36
Chism, D. D., Silva, D. D., & Whang, Y. E. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.928594 · Cited by 39
Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation
Steinberger, A. E., Cotogno, P., Ledet, E. M., Lewis, B. E., & Sartor, O. A. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.09.001 · Cited by 33
Self-citationBone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
Iagaru, A. H., Mittra, E., Colletti, P. M., & Jadvar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170746 · Cited by 33
Early use of chemotherapy in metastatic prostate cancer
Markowski, M. C., & Carducci, M. A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.017 · Cited by 36
Sonpavde, G., McMannis, J. D., Bai, Y., Seethammagari, M. R., Bull, J. M., Hawkins, V., Dancsak, T., Lapteva, N., Levitt, J. M., Moseley, A. B., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2027-6 · Cited by 35
Sartor, O. A., Heinrich, D. A., Mariados, N. F., Vidal, M., Keizman, D., Karlsson, C. T., Peer, A., Procopio, G., Frank, S. J., Pulkkanen, K. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx331 · Cited by 33
“Discontinued treatmenta n = 15 (radiographic progression [4], clinical progression [6], AE not associated with clinical progression [3], patient request [2])”
BackgroundInfluentialSelf-citationHealth-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review
Kretschmer, A., Ploussard, G., Heidegger, I. M., Tsaur, I., Borgmann, H., Surcel, C. I., Mathiéu, R., Visschere, P. D., Valério, M., van den Bergh, R. C. N., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2020.01.017 · Cited by 35
Lawal, I. O., Mokoala, K. M. G., Mahapane, J., Kleynhans, J., Meckel, M., Vorster, M., Ebenhan, T., Rösch, F., & Sathekge, M. M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04867-y · Cited by 35
c-Met expression in renal cell carcinoma with bone metastases
Paiva, R. S., Gomes, I., Casimiro, S., Fernandes, I., & Costa, L. (2020) · Journal of bone oncology · doi:10.1016/j.jbo.2020.100315 · Cited by 37
Labriola, M., Atiq, S. O., Hirshman, N. A., & Bitting, R. L. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00299-9 · Cited by 34
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020)
del Alba, A. G., Méndez-Vidal, M. J., Vazquez, S., Castro, E., Climent, M. A., Gallardo, E., González‐Billalabeitia, E., Lorente, D., Maroto, P., & Arranz, J. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02561-5 · Cited by 38
Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment
Carthon, B. C., Sibold, H. C., Blee, S. M., & Pentz, R. D. (2021) · The Oncologist · doi:10.1002/onco.13749 · Cited by 38
“Radium-223 was recently approved because of an overall survival benefit and pain relief in men with symptomatic bone metastases and castration-resistant prostate cancer [106].”
Sethakorn, N., Héninger, E., Sánchez‐de‐Diego, C., Ding, A. B., Yada, R. C., Kerr, S. C., Kosoff, D., Beebe, D. J., & Lang, J. M. (2022) · Cancers · doi:10.3390/cancers14030757 · Cited by 34
“Radiopharmaceuticals such as radium-223 deposit only in bone and are approved in PC with bone-only metastasis; however the effect on prolonging survival is modest [97].”
BackgroundFred Saad, C., Aprikian, A. G., Finelli, A., Fleshner, N. E., Gleave, M. E., Kapoor, A., Niazi, T. M., North, S. A., Pouliot, F., Rendon, R., et al. (2022) · Canadian Urological Association Journal · doi:10.5489/cuaj.8161 · Cited by 39
Schutz, F. A. B., Buzaid, A. C., & Sartor, O. A. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.02.003 · Cited by 39
Self-citationProstate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling
Qin, W., Zheng, Y., Qian, B., & Zhao, M. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00153 · Cited by 33
“, 2010), and a bone targeting alpha-emitting radionuclide, radium-223 chloride (Parker et al., 2013; Gillessen et al., 2015).”
BackgroundTargeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects
Lacœuille, F., Arlicot, N., & Faivre-Chauvet, A. (2018) · Médecine Nucléaire · doi:10.1016/j.mednuc.2017.12.002 · Cited by 41
McKay, R. R., Bossé, D., Gray, K. P., Michaelson, M. D., Krajewski, K. M., Jacene, H. A., Walsh, M. K., Joaquim Bellmunt, B., Pomerantz, M. M., Harshman, L. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3577 · Cited by 35
“Its efficacy was demonstrated in the ALSYMPCA trial, where men with castrate-resistant prostate cancer treated with radium-223 had superior overall survival (OS) and longer time to first SSE compared with placebo (9).”
BackgroundGrochtdreis, T., König, H., Dobruschkin, A., Amsberg, G. V., & Dams, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208063 · Cited by 36
“Besides docetaxel, which has proven life-prolonging efficacy for patients with mCRPC, also the therapeutic agents abiraterone, cabazitaxel, enzalutamide, the immunotherapeutic sipuleucel-T and the radionuclide radium-223 showed significant survival advantages [16, 17, 29].”
BackgroundMcManus, H. D., Dorff, T., Morgans, A. K., Sartor, O., Shore, N., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00906-z · Cited by 32
Self-citationPalecki, J., Bhasin, A., Bernstein, A., Mille, P. J., Tester, W. J., Kelly, W. K., & Zarrabi, K. K. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2356820 · Cited by 33
Uprimny, C., Kroiss, A. S., Nilica, B., Buxbaum, S., Decristoforo, C., Horninger, W., & Virgolini, I. J. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2922-4 · Cited by 32
A Perspective of Immunotherapy for Prostate Cancer
Silvestri, I., Cattarino, S., Giantulli, S., Nazzari, C., Collalti, G., & Sciarra, A. (2016) · Cancers · doi:10.3390/cancers8070064 · Cited by 34
Ueda, Y., Matsubara, N., Tabata, K., Satoh, T., Kamiya, N., Suzuki, H., Kawahara, T., & Uemura, H. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.07.026 · Cited by 33
“A new agent, radium-223, a high energy a-particle radiation, did not decrease the serum PSA levels but did prolong OS compared with placebo, placing into question the role of the PSA level as an estimate of patient survival.(7) Thus, we can assume that the significance and magnitude of a decline in the PSA level as a…”
BackgroundCrawford, E. D., Petrylak, D. P., Shore, N. D., Saad, F., Slovin, S. F., Vogelzang, N. J., Keane, T. E., Koo, P. J., Gomella, L. G., O’Sullivan, J. M., et al. (2017) · Urology · doi:10.1016/j.urology.2016.12.033 · Cited by 33
Self-citationMcNamara, M. A., Sweeney, C. J., Antonarakis, E. S., & Armstrong, A. J. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0014-9 · Cited by 35
“Once castrate-resistant disease develops, approved therapies for metastatic castrate-resistant prostate cancer (mCRPC), including sipuleucel-T [2], enzalutamide [3, 4], abiraterone [5, 6], docetaxel [7], cabazitaxel [8], or radium-223 [9], are added to ADT and are associated with modest survival benefits [10].”
BackgroundFrantellizzi, V., Farcomeni, A., Follacchio, G. A., Pacilio, M., Pellegrini, R., Pani, R., & VINCENTIS, G. D. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1228-6 · Cited by 34
Lee, D., Li, M., Bednarz, B. P., & Schultz, M. K. (2018) · Radiation Research · doi:10.1667/rr15081.1 · Cited by 34
“, Whippany, NJ], has provided evidence of the promise of alpha-particle therapy for cancer by significantly improving the median overall survival of metastatic castration-resistant prostate-cancer patients (mCRPC), with minimal reported toxicity (3, 21).”
Carles, J., Castellano, D., Méndez-Vidal, M. J., Mellado, B., Medina, M. I. S., del Alba, A. G., Perez‐Gracia, J. L., Jimenez, J., Suárez, C., Sepúlveda-Sánchez, J. M., et al. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.07.013 · Cited by 32
Palliation of bone metastases—exploring options beyond radiotherapy
Saravana-Bawan, S., David, E., Sahgal, A., & Chow, E. (2019) · Annals of Palliative Medicine · doi:10.21037/apm.2018.12.04 · Cited by 32
“There is increasing use of radiopharmaceuticals especially for prostate cancer with a recent randomized trial evaluating radium 226 in castrate resistant prostate cancer showed a survival advantage (11).”
Background223Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
Benabdallah, N., Bernardini, M., Bianciardi, M., de Labriolle-Vaylet, C., Franck, D., & Desbrée, A. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0488-7 · Cited by 32
150 years of the periodic table: New medicines and diagnostic agents
Imberti, C., & Sadler, P. J. (2020) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2019.11.001 · Cited by 32
Jagodinsky, J. C., & Morris, Z. S. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.008 · Cited by 32
Brighi, N., Conteduca, V., Lolli, C., Gurioli, G., Schepisi, G., Palleschi, M., Mariotti, M., Casadei, C., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103199 · Cited by 33
Khreish, F., Wiessner, M., Rosar, F., Ghazal, Z., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · Biomolecules · doi:10.3390/biom11081099 · Cited by 35
The value of anticancer drugs — a regulatory view
Pignatti, F., Wilking, U., Postmus, D., Wilking, N. E., Delgado, J., & Bergh, J. C. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00584-z · Cited by 37
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo
Yehya, A., Ghamlouche, F., Zahwe, A., Zeid, Y., Wakimian, K., Mukherji, D., & Abou-Kheir, W. G. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.15 · Cited by 37
Bellavia, M. C., Patel, R. B., & Anderson, C. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264373 · Cited by 47
“From a landmark phase III clinical trial (NCT00699751), Xofigo was demonstrated to significantly extend time to the first symptomatic skeletal event and overall survival (54).”
BackgroundTakalkar, A. M., Adams, S., & Subbiah, V. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-23 · Cited by 32
Radium and other alpha emitters in prostate cancer
Sartor, O. A., & Sharma, D. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.02.07 · Cited by 36
“Based on these pivotal data (19), (223)Ra therapy was approved by regulatory agencies around the world.”
BackgroundMethodSelf-citationRoy, S., & Morgan, S. C. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.04.012 · Cited by 34
Cofano, F., Monticelli, M., Ajello, M., Zenga, F., Marengo, N., Perna, G. D., Altieri, R., Cassoni, P., Bertero, L., Melcarne, A., et al. (2019) · Cancer Control · doi:10.1177/1073274819870549 · Cited by 33
“The use of these agents in combination with Docetaxel has recently shown benefit in terms of OS.72 Tumor progression to the androgen-resistant (or castrationresistant) stage is generally lethal and characterized clinically by bone metastases.73 The mechanisms of resistance generally involve androgen pathways and inclu…”
BackgroundInfluentialMaffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04660-6 · Cited by 33
Halabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02661 · Cited by 30
“Current frontline therapies for men with metastatic, castration-resistant prostate cancer (mCRPC) are AR-targeted therapy, chemotherapy, and bone-targeting radiopharmaceutical.(2-8) Despite the benefit of these therapies, approximately 20% of men have primary resistance, whereas acquired resistance occurs in most men…”
BackgroundAl‐Ibraheem, A., Brink, A., Lee, S. T., Reyes, A. D. L., Páez, D., Craviolatti, P. S., Llamas‐Olier, A., Giammarile, F., Abdlkadir, A. S., Lobato, E. E., et al. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.07.005 · Cited by 36
McNamara, M. A., & George, D. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1390-y · Cited by 31
Koo, K. C., Park, S. U., Kim, K. H., Rha, K. H., Hong, S. J., Yang, S. C., & Chung, B. H. (2015) · Yonsei Medical Journal · doi:10.3349/ymj.2015.56.5.1206 · Cited by 31
Dan, T., Eldredge-Hindy, H., Hoffman-Censits, J. H., Lin, J., Kelly, W. K., Gomella, L. G., Lallas, C. D., Trabulsi, E. J., Hurwitz, M., Dicker, A. P., et al. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000181 · Cited by 32
Joshi, R., Goihberg, E., Ren, W., Pilichowska, M. E., & Mathew, P. F. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1212139 · Cited by 31
“Currently the only niche-directed therapeutics in prostate cancer is represented by bone-homing radioisotopes that modestly impact survival and skeletalrelated events.(2,3) The clinical observations that bone metastases from”
BackgroundOverbeek, F., de Klerk, J. M. H., Jong, P. C. M. P.-D., van den Berk, A., ter Heine, R., Rodenburg, C. J., Kooistra, A., Hendrikse, N. H., Bloemendal, H. J., & Lange, R. (2016) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0828-16-05 · Cited by 31
Buttigliero, C., Pisano, C., Tucci, M., Vignani, F., Bertaglia, V., Iaconis, D., Guglielmini, P., Numico, G., Scagliotti, G. V., & Maïo, M. D. (2017) · Acta Oncologica · doi:10.1080/0284186x.2016.1260772 · Cited by 33
“Finally, in 2013, radium-223, an a-emitting radium isotope, became available to clinical practice on the basis of the results of a randomized phase III study that demonstrated a significant delay in time to first skeletal symptomatic event and an improvement in OS in symptomatic bone mCRPC patients [9].”
Background68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
Zang, S., Shao, G., Cui, C., Li, T., Huang, Y., Yao, X., Fan, Q., Chen, Z., Du, J., Jia, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14691 · Cited by 36
Treatment strategies for DNA repair-deficient prostate cancer
Teply, B. A., & Antonarakis, E. S. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1338138 · Cited by 33
“leucel-T [3]), and leveraging cytotoxic mechanisms of action (cabazitaxel [4], radium-223 [5]).”
BackgroundRadioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Awang, Z. H., Essler, M., & Ahmadzadehfar, H. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1037-7 · Cited by 35
O’Sullivan, J. M., Heinrich, D. A., James, N. D., Nilsson, S. F., Ost, P., Parker, C. C., & TOMBAL, B. F. (2018) · European Urology · doi:10.1016/j.eururo.2018.11.003 · Cited by 29
“This licence was based on the improvement in overall survival (OS) demonstrated (hazard ratio [HR] 0.7) in the ALSYMPCA registration trial, which compared six cycles of radium-223 plus best standard of care to placebo plus best standard of care [2].”
BackgroundInfluentialSelf-citationTsumura, H., Ishiyama, H., Tabata, K., Sekiguchi, A., Kawakami, S., Satoh, T., Kitano, M., & Iwamura, M. (2018) · The Prostate · doi:10.1002/pros.23757 · Cited by 32
“Historically, the presence of metastasis was considered as incurable disease and androgen deprivation therapy (ADT) alone was mainly indicated for initial treatments in metastatic prostate cancer (mPCa) patients.(1) The treatment for these diseases usually focused on palliative intent.”
BackgroundO’Sullivan, J. M., Carles, J., Cathomas, R. L., Iturriaga, A. G., Heinrich, D. A., Kramer, G., Ost, P., van Oort, I. M., & TOMBAL, B. F. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.02.007 · Cited by 34
Self-citationFred Saad, C., Aprikian, A. G., Finelli, A., Fleshner, N. E., Gleave, M. E., Kapoor, A., Niazi, T. M., North, S. A., Pouliot, F., Rendon, R., et al. (2019) · Canadian Urological Association Journal · doi:10.5489/cuaj.6136 · Cited by 34
Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
Weiner, A. B., Nettey, O. S., & Morgans, A. K. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0668-8 · Cited by 36
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.